KBC Group
ARQT icon

KBC Group’s Arcutis Biotherapeutics ARQT Stock Holding History

KBC Group’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$116K Hold
4,376
– – ﹤0.01% 1297
2026
Q2 		$115K Hold
4,376
– – ﹤0.01% 1329
2026
Q1 		$103K Buy
4,376
+1,321
+43% +$33.7K ﹤0.01% 1300
2025
Q4 		$89K Hold
3,055
– – ﹤0.01% 1358
2025
Q3 		$58K Hold
3,055
– – ﹤0.01% 1591
2025
Q2 		$43K Sell
3,055
-2,313
-43% -$32.4K ﹤0.01% 1654
2025
Q1 		$84K Buy
+5,368
New +$75.6K ﹤0.01% 1582

Other funds holding ARQT

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Perpetual Ltd
Perpetual Ltd Sydney, New South Wales, Australia $6.57B AUM 14.15% 1-Year Est. Return
Simplify Asset Management
Simplify Asset Management Las Vegas, Nevada $6.11B AUM 3.71% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Jay A. Fishman Ltd
Jay A. Fishman Ltd Troy, Michigan $1.24B AUM 21.21% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Privium Fund Management
Privium Fund Management Amsterdam, Netherlands $516M AUM 18.66% 1-Year Est. Return

KBC Group's ARQT Position: Q3 2026 in Review

KBC Group held its Arcutis Biotherapeutics (ARQT) position steady in Q3 2026 at 4,376 shares worth $116K. The position accounts for ﹤0.01% of the portfolio, ranked #1297.

KBC Group first reported a position in ARQT in Q1 2025 and has held it in 7 quarters since. 112 funds tracked by Wall St. Rank hold ARQT as of Q3 2026.

  • KBC Group held 4,376 shares of Arcutis Biotherapeutics worth $116K as of Q3 2026.
  • KBC Group left its Arcutis Biotherapeutics share count unchanged in Q3 2026.
  • Arcutis Biotherapeutics made up ﹤0.01% of KBC Group's portfolio in Q3 2026, its #1297 holding.
  • KBC Group first reported a position in Arcutis Biotherapeutics in Q1 2025 and has held it in 7 quarters since.
  • 112 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q3 2026.

Based on KBC Group's 13F filing for Q3 2026, filed 22 Oct 2026.